Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

A 30-year-old woman with galactorrhea

Ipsita Ray and Roland M. Jones
CMAJ April 14, 2020 192 (15) E397-E398; DOI: https://doi.org/10.1503/cmaj.190750
Ipsita Ray
Centre for Addiction and Mental Health (Ray, Jones); Department of Psychiatry (Jones), University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland M. Jones
Centre for Addiction and Mental Health (Ray, Jones); Department of Psychiatry (Jones), University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Metrics
  • Responses
  • PDF
Loading

A 30-year-old woman with a diagnosis of schizophrenia presents to her family doctor. She was discharged from a psychiatric facility 2 weeks earlier after treatment for relapse of psychosis. She commenced treatment with paliperidone (a second-generation antipsychotic medication) 6 mg/d 6 weeks before discharge from the psychiatric facility, and she has responded well to the treatment. The psychosis is in remission; however, the patient is reluctant to continue with the treatment and requests that the medication be stopped.

What further questions should be asked on history?

It is important to ask about the adverse effects of antipsychotic medications, including galactorrhea and amenorrhea. Women often feel uncomfortable reporting information about reproductive adverse effects.1 On direct questioning, the patient reports that she has been lactating for the past 3 weeks and that her menstrual cycle has been irregular. Hyperprolactinemia should be considered, and a detailed drug and medical history should be taken to consider possible causes (see Box 1 for causes of hyperprolactinemia to be considered).

Box 1:

Causes of hyperprolactinemia2,3

Pharmacologic

  • Antipsychotic medications

  • Antidepressant medications (imipramine, amitriptyline, clomipramine)

  • Antiemetic medications (metoclopramide, domperidone, cimetidine)

  • Antihypertensive medications

  • Estrogen medications

  • Verapamil

Physiological

  • Pregnancy

  • Lactation

  • Stress

  • Breast stimulation

  • Macroprolactin

Pathologic

  • Pituitary tumours

  • Chronic renal failure

  • Cirrhosis

  • Primary hypothyroidism

  • Cushing disease

  • Acromegaly

What should be considered on physical examination?

On physical examination, there is bilateral milky secretion from the nipples, consistent with galactorrhea. Examination of the visual fields is normal (bitemporal hemianopia, a common finding in pituitary tumours, is important to consider in all cases of hyperprolactinemia).

Should further investigations be ordered?

The patient’s serum prolactin level was 130 μg/L (2756 mIU/L) (normal range 0–25 μg/L [0–530 mIU/L] in nonpregnant women, 0–20 μg/L [0–424 mIU/L] in men). Pregnancy was ruled out through blood and urine pregnancy tests. Blood tests, including renal, hepatic and thyroid function tests, were conducted.4 If the elevated prolactin level does not coincide with antipsychotic therapy, or does not reduce in response to adjusting the treatment, magnetic resonance imaging (MRI) of the brain should be done to investigate for an abnormality in the hypothalamopituitary region.5

In this patient, the direct correlation between treatment with antipsychotic medication and the start of symptoms points to the most probable diagnosis of antipsychotic-induced hyperprolactinemia. If findings are equivocal, a referral to an endocrinologist should be considered. Treatment with antipsychotic medication can frequently cause increases in prolactin up to around 4 times the normal upper range. Prolactin levels that are orders of magnitude higher are less likely to be caused by antipsychotic medication, and other causes should be considered.

Hyperprolactinemia is caused by blockade of dopamine D2 receptors in the tuberoinfundibular system of the hypothalamus. Elevated prolactin levels inhibit luteinizing hormone and follicle-stimulating hormone, leading to low estradiol and progesterone, and abnormalities in testosterone levels. Marked prolactin excess (> 100 μg/L [> 2120 mIU/L]), is associated with hypogonadism, galactorrhea, hirsutism, acne, sexual dysfunction, atrophic changes in vaginal mucosa, amenorrhea and osteopenia with associated risk of fractures.6 These effects are distressing and can cause long-term harm. Antipsychotic medications can cause menstrual disorders in 15%–50% of women owing to increased prolactin levels.7 Between 48% and 93% of premenopausal women and 42%–47% of men taking antipsychotic medications have hyperprolactinemia, with the effect being directly dose related.2

How should this case be managed?

Once antipsychotic treatment is confirmed as the cause of the raised prolactin level, the following steps should be considered: a dose reduction if the patient’s mental state is stable, aiming for the lowest effective therapeutic dose of the antipsychotic medication; and substituting the antipsychotic with one that has a lower propensity to elevate prolactin, weighing the benefits of making the change with the risk of precipitating a relapse of psychosis (Box 2).

Box 2:

Relative effect of antipsychotic medications on prolactin level8,9

View this table:
  • View inline
  • View popup
  • Download powerpoint

Case revisited

The patient’s history and investigations were consistent with antipsychotic-induced hyperprolactinemia. She was provided with education about the cause of her symptoms and the role of the antipsychotic medication. The dose of paliperidone was reduced from 6 mg to 3 mg. She returned for a follow-up visit after a month; repeat prolactin measurement showed her level was still high, and she continued to lactate. Paliperidone was discontinued and substituted with aripiprazole at a dose of 15 mg/d. Aripiprazole is licensed for the treatment of schizophrenia and is associated with a less than 5% rate of hyperprolactinemia.10 This treatment plan was successful. The psychosis remained in remission, and the patient’s prolactin level started to decrease and return to normal. After 2 months she stopped lactating, and by 4 months her menstrual cycle became regular.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • The clinical scenario is fictional.

  • Contributors: Both authors contributed to drafting the work, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

References

  1. ↵
    1. Dickson RA,
    2. Glazer WM
    . Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35:S75–86.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Holt RI
    . Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 2008;22(Suppl 2):28–37.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bargiota SI,
    2. Bonotis KS,
    3. Messinis IE,
    4. et al
    . The effects of antipsychotics on prolactin levels and women’s menstruation. Schizophr Res Treatment 2013;2013:502697. doi: 10.1155/2013/502697. Epub 2013 Dec 24.
    OpenUrlCrossRef
  4. ↵
    1. Prabhakar VK,
    2. Davis JR
    . Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol 2008;22:341–53.
    OpenUrlPubMed
  5. ↵
    1. Melmed S,
    2. Casanueva FF,
    3. Hoffman AR,
    4. et al
    . Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–88.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Serri O,
    2. Chik CL,
    3. Ur E,
    4. et al
    . Diagnosis and management of hyperprolactinemia. CMAJ 2003;169:575–81.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Santoni JP,
    2. Saubadu S
    . Adverse events associated with neuroleptic drugs: focus on neuroendocrine reactions. Acta Ther 1995;21:193–204.
    OpenUrl
  8. ↵
    1. Taylor D,
    2. Barnes TRE,
    3. Young AH
    . The Maudsley prescribing guidelines. 13th ed. Wiley-Blackwell; 2018.
  9. ↵
    1. Leucht S,
    2. Cipriani A,
    3. Spineli L,
    4. et al
    . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;482:951–62.
    OpenUrl
  10. ↵
    1. Kane JM,
    2. Meltzer HY,
    3. Carson WH Jr.,
    4. et al
    . Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68:213–23.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (15)
CMAJ
Vol. 192, Issue 15
14 Apr 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A 30-year-old woman with galactorrhea
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A 30-year-old woman with galactorrhea
Ipsita Ray, Roland M. Jones
CMAJ Apr 2020, 192 (15) E397-E398; DOI: 10.1503/cmaj.190750

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
A 30-year-old woman with galactorrhea
Ipsita Ray, Roland M. Jones
CMAJ Apr 2020, 192 (15) E397-E398; DOI: 10.1503/cmaj.190750
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • What further questions should be asked on history?
    • What should be considered on physical examination?
    • Should further investigations be ordered?
    • How should this case be managed?
    • Case revisited
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Asymptomatic hydrocephalus
  • How to use antihistamines
  • Pseudoaneurysm of the brachial artery in a patient who uses intravenous drugs
Show more Practice

Similar Articles

Collections

  • Areas of Focus
    • Mental health
  • Sections
    • Decisions
  • Topics
    • Psychiatry & mental health: adult
    • Women's health (including abortion)
    • Drugs: adverse reactions
    • Drugs: psychotherapeutic

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire